ImmuPharma PLC (LON:IMM)
3.72p+0.54%
Spriggl Score: Poor— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“New cash extends runway to 2028, but unsigned licensing deal keeps this binary outcome highly speculative.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About ImmuPharma PLC
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-b…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £24.8M
Recent dividends
- 14 Dec 20213.00p
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across ImmuPharma PLC and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free